David Steinberg
Stock Analyst at Jefferies
(2.87)
# 1,514
Out of 5,173 analysts
33
Total ratings
64%
Success rate
26.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Steinberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHC Bausch Health Companies | Downgrades: Hold | $12 → $8 | $5.01 | +59.68% | 7 | Feb 6, 2025 | |
| PRGO Perrigo Company | Upgrades: Buy | $45 → $63 | $9.25 | +581.08% | 8 | Sep 30, 2021 | |
| SUPN Supernus Pharmaceuticals | Upgrades: Buy | $25 → $40 | $47.76 | -16.25% | 11 | Apr 13, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $151 → $188 | $180.62 | +4.09% | 5 | Oct 9, 2020 | |
| OCUL Ocular Therapeutix | Initiates: Buy | $8 | $8.18 | -2.20% | 1 | Mar 17, 2020 | |
| SVRA Savara | Initiates: Buy | $20 | $4.96 | +303.23% | 1 | Sep 22, 2017 |
Bausch Health Companies
Feb 6, 2025
Downgrades: Hold
Price Target: $12 → $8
Current: $5.01
Upside: +59.68%
Perrigo Company
Sep 30, 2021
Upgrades: Buy
Price Target: $45 → $63
Current: $9.25
Upside: +581.08%
Supernus Pharmaceuticals
Apr 13, 2021
Upgrades: Buy
Price Target: $25 → $40
Current: $47.76
Upside: -16.25%
Jazz Pharmaceuticals
Oct 9, 2020
Maintains: Buy
Price Target: $151 → $188
Current: $180.62
Upside: +4.09%
Ocular Therapeutix
Mar 17, 2020
Initiates: Buy
Price Target: $8
Current: $8.18
Upside: -2.20%
Savara
Sep 22, 2017
Initiates: Buy
Price Target: $20
Current: $4.96
Upside: +303.23%